{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:02:10Z","timestamp":1790182930999,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Science and Technology","award":["MOST105-2314-B-002-088-MY3"],"award-info":[{"award-number":["MOST105-2314-B-002-088-MY3"]}]},{"name":"Ministry of Science and Technology","award":["MOST105-2314-B-002-190-MY2"],"award-info":[{"award-number":["MOST105-2314-B-002-190-MY2"]}]},{"name":"Ministry of Science and Technology","award":["MOST106-2811-B-002-038"],"award-info":[{"award-number":["MOST106-2811-B-002-038"]}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"crossref","award":["NTUH106-EDN09"],"award-info":[{"award-number":["NTUH106-EDN09"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes, Taiwan","doi-asserted-by":"crossref","award":["NHRI-EX106-10608BI"],"award-info":[{"award-number":["NHRI-EX106-10608BI"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ejca.2018.07.010","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T18:05:14Z","timestamp":1533924314000},"page":"10-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia\u2013mutated kinase\u2013mediated DNA damage response"],"prefix":"10.1016","volume":"102","author":[{"given":"Chao-Yuan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Shu","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7426-0743","authenticated-orcid":false,"given":"Cheng-Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Shin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hsien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Hsin","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-Wen","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ting","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-I","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4686-7019","authenticated-orcid":false,"given":"Kuen-Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2018.07.010_bib1","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2018.07.010_bib2","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ejca.2018.07.010_bib3","series-title":"Cancer facts & figures 2018","author":"Society","year":"2018"},{"issue":"1","key":"10.1016\/j.ejca.2018.07.010_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.ejca.2018.07.010_bib5","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","article-title":"Hepatocellular carcinoma","volume":"365","author":"El-Serag","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.ejca.2018.07.010_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdt054","article-title":"Intermediate hepatocellular carcinoma: current treatments and future perspectives","volume":"24","author":"Dufour","year":"2013","journal-title":"Ann Oncol"},{"issue":"10064","key":"10.1016\/j.ejca.2018.07.010_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.ejca.2018.07.010_bib8","doi-asserted-by":"crossref","first-page":"46750","DOI":"10.18632\/oncotarget.8775","article-title":"The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets","volume":"7","author":"Chong","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejca.2018.07.010_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.07.010_bib10","article-title":"Preclinical and clinical development of palbociclib and future perspectives","author":"de Duenas","year":"2018","journal-title":"Clin Transl Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2018.07.010_bib11","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/1878-0261.12072","article-title":"Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4\/6-independent manner","volume":"11","author":"Hsieh","year":"2017","journal-title":"Mol Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2018.07.010_bib12","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/gutjnl-2016-312268","article-title":"Palbociclib (PD-0332991), a selective CDK4\/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma","volume":"66","author":"Bollard","year":"2017","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.ejca.2018.07.010_bib13","article-title":"A phase II study of palbociclib (PD-0332991) in adult patients with advanced hepatocellular carcinoma","volume":"33","author":"Littman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2018.07.010_bib14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clon.2013.06.007","article-title":"Biological consequences of radiation-induced DNA damage: relevance to radiotherapy","volume":"25","author":"Lomax","year":"2013","journal-title":"Clin Oncol"},{"issue":"7267","key":"10.1016\/j.ejca.2018.07.010_bib15","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"issue":"7381","key":"10.1016\/j.ejca.2018.07.010_bib16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ejca.2018.07.010_bib17","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol Cell"},{"issue":"18","key":"10.1016\/j.ejca.2018.07.010_bib18","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1158\/0008-5472.CAN-08-0763","article-title":"Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation","volume":"68","author":"Rainey","year":"2008","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2018.07.010_bib19","first-page":"337","article-title":"Small molecule inhibitors of DNA-PK for tumor sensitization to anticancer therapy","volume":"68","author":"Pospisilova","year":"2017","journal-title":"J Physiol Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2018.07.010_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.chembiol.2014.11.013","article-title":"DNA double-strand break repair inhibitors as cancer therapeutics","volume":"22","author":"Srivastava","year":"2015","journal-title":"Chem Biol"},{"issue":"11","key":"10.1016\/j.ejca.2018.07.010_bib21","first-page":"1519","article-title":"Inhibition of DNA damage repair by the CDK4\/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth","volume":"18","author":"Hashizume","year":"2016","journal-title":"Neuro Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2018.07.010_bib22","doi-asserted-by":"crossref","first-page":"14690","DOI":"10.1074\/jbc.C700019200","article-title":"Mice lacking protein phosphatase 5 are defective in ataxia telangiectasia mutated (ATM)-mediated cell cycle arrest","volume":"282","author":"Yong","year":"2007","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.ejca.2018.07.010_bib23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1101\/gad.1176004","article-title":"Requirement of protein phosphatase 5 in DNA-damage-induced ATM activation","volume":"18","author":"Ali","year":"2004","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.ejca.2018.07.010_bib24","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.bbrc.2010.12.005","article-title":"Protein phosphatase 5 is necessary for ATR-mediated DNA repair","volume":"404","author":"Kang","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"22","key":"10.1016\/j.ejca.2018.07.010_bib25","doi-asserted-by":"crossref","first-page":"9910","DOI":"10.1128\/MCB.25.22.9910-9919.2005","article-title":"Protein phosphatase 5 is required for ATR-mediated checkpoint activation","volume":"25","author":"Zhang","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.ejca.2018.07.010_bib26","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1073\/pnas.0307765100","article-title":"DNA-PKcs function regulated specifically by protein phosphatase 5","volume":"101","author":"Wechsler","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"10.1016\/j.ejca.2018.07.010_bib27","doi-asserted-by":"crossref","first-page":"8984","DOI":"10.1073\/pnas.0501895102","article-title":"In\u00a0vivo formation and repair of DNA double-strand breaks after computed tomography examinations","volume":"102","author":"Lobrich","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2018.07.010_bib28","article-title":"Immunofluorescence microscopy of gammaH2AX and 53BP1 for analyzing the formation and repair of DNA Double-strand Breaks","volume":"129","author":"Popp","year":"2017","journal-title":"J Vis Exp"},{"issue":"24","key":"10.1016\/j.ejca.2018.07.010_bib29","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM","volume":"64","author":"Hickson","year":"2004","journal-title":"Cancer Res"},{"issue":"32","key":"10.1016\/j.ejca.2018.07.010_bib30","doi-asserted-by":"crossref","first-page":"33992","DOI":"10.1074\/jbc.M402855200","article-title":"Structural basis for the catalytic activity of human serine\/threonine protein phosphatase-5","volume":"279","author":"Swingle","year":"2004","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.ejca.2018.07.010_bib31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O'Leary","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2018.07.010_bib32","first-page":"805","article-title":"The development of ataxia telangiectasia mutated kinase inhibitors","volume":"14","author":"Andrs","year":"2014","journal-title":"Mini Rev Med Chem"},{"issue":"39","key":"10.1016\/j.ejca.2018.07.010_bib33","doi-asserted-by":"crossref","first-page":"41794","DOI":"10.18632\/oncotarget.5993","article-title":"Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun\/COX-2 signaling pathway","volume":"6","author":"Qin","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.ejca.2018.07.010_bib34","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/15384101.2017.1320005","article-title":"The CDK4\/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia","volume":"16","author":"Zhang","year":"2017","journal-title":"Cell Cycle"},{"issue":"3","key":"10.1016\/j.ejca.2018.07.010_bib35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jpba.2010.02.031","article-title":"Quantitative analysis of PD 0332991 in xenograft mouse tumor tissue by a 96-well supported liquid extraction format and liquid chromatography\/mass spectrometry","volume":"53","author":"Nguyen","year":"2010","journal-title":"J Pharm Biomed Anal"},{"issue":"13","key":"10.1016\/j.ejca.2018.07.010_bib36","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1158\/1078-0432.CCR-16-3157","article-title":"Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4\/6 inhibitor in various solid tumors","volume":"23","author":"Tripathy","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2018.07.010_bib37","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1021\/acschembio.5b00368","article-title":"Chemoproteomics reveals novel protein and lipid kinase targets of clinical CDK4\/6 inhibitors in lung cancer","volume":"10","author":"Sumi","year":"2015","journal-title":"ACS Chem Biol"},{"issue":"47","key":"10.1016\/j.ejca.2018.07.010_bib38","doi-asserted-by":"crossref","first-page":"40413","DOI":"10.1074\/jbc.M111.244053","article-title":"Disruption of serine\/threonine protein phosphatase 5 (PP5:PPP5c) in mice reveals a novel role for PP5 in the regulation of ultraviolet light-induced phosphorylation of serine\/threonine protein kinase Chk1 (CHEK1)","volume":"286","author":"Amable","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2018.07.010_bib39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bcp.2017.05.010","article-title":"Protein phosphatase 5 promotes hepatocarcinogenesis through interaction with AMP-activated protein kinase","volume":"138","author":"Chen","year":"2017","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2018.07.010_bib40","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s12010-014-1281-8","article-title":"Knockdown of PPP5C inhibits growth of hepatocellular carcinoma cells in\u00a0vitro","volume":"175","author":"Feng","year":"2015","journal-title":"Appl Biochem Biotechnol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918309699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918309699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T23:48:01Z","timestamp":1589932081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918309699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":40,"alternative-id":["S0959804918309699"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.07.010","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia\u2013mutated kinase\u2013mediated DNA damage response","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}